Global Prosthetic Heart Valve Market is valued approximately USD 6.9 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 11.10 % over the forecast period 2022-2028. Prosthetic heart valves are artificial valves that are used to replace dysfunctional native valves. Prosthetic heart Valves are categorized into three types mechanical heart valves, bioprosthetic valves, and homografts. The rise in prevalence of valvular heart disease Worldwide and growing demand for minimally invasive surgeries as well as Strategic initiatives from leading market players are key factors propelling the market growth. For Instance – according to American College of Cardiology estimates – as of 2020, each year more than 5 million Americans are diagnosed with Valvular Heart Disease (VHD). In addition, around 500,000 VHD patients suffer from severe Aortic Stenosis (AS). Moreover, as per the European Society of Cardiology (ESC) – as of 2021, around 13% of people aged 75 and older in high-income countries are affected by VHD. Further, in September 2021, Abbott announced that it has received FDA approval for its Epic? Plus and Epic Plus Supra Stented Tissue Valves. These two valves are intended for the treatment of aortic or mitral valve disease. Also, an increase in the number of geriatric individuals, as well as rising trend of sedentary lifestyle, would create lucrative growth opportunities for the Prosthetic Heart Valve Market during the forecast period. However, various factors such as high treatment costs and complications associated with the use of prosthetic heart valves as well unfavourable reimbursement scenarios the growth of the market over the forecast period of 2022-2028.

The key regions considered for the Global Prosthetic Heart Valve Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share owing to factors such as the increasing prevalence of lifestyle disorders such as diabetes and obesity as well as the presence of leading market players in the region. The Asia Pacific is anticipated to be the fastest-growing region during the forecast period. Factors such as increasing incidences of cardiac disorders such as aortic stenosis, and the rising healthcare infrastructure in countries like China, and India would create lucrative growth opportunities for the market in the Asia Pacific region.

Major market player included in this report are:
Meril Lifesciences
Boston Scientific Corporation
Micro Interventional Devices, Inc.
Direct Flow medical, Inc.
Edwards Lifesciences Corporation
LivaNova PLC.
JenaValve Technology, Inc.
CryoLife, Inc.
The objective of the study is to define the market sizes of different segments & countries in recent years and to forecast the values for the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product:
Mechanical Heart Valve
Tissue Heart Valve
Transcatheter Heart Valve
By Region:
North America

Asia Pacific
South Korea
Latin America
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Prosthetic Heart Valve Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers